The FDA backed a so-called “female Viagra” drug on Thursday, and now, the stock of a company that’s making a similar drug is surging.
Palatin Technologies jumped more than 46% in early trading on Friday.
The FDA’s advisory committee voted 18-6 in favour of flibanserin, designed to boost women’s psychological desire for sex. Business Insider’s Erin Brodwin has the full details of what the drug is being designed to do.
Palatin has a market cap of $US55 million, and its shares climbed to as high as $US1.58 in trading on Friday morning.
But the drug could be huge for the company although it’s being developed by Sprout Pharmaceuticals, a private company.
Palatin is developing bremelanotide, another drug for female sexual dysfunction, according to Reuters.
In a note, Canaccord Genuity analysts raised their price target to $US6 from $US4, and maintained their “buy” rating.
“We believe this has significant read through for PTN, since this will possibly be the first drug to be approved
for female sexual dysfunction given the twice rejection from the FDA on Flibanserin
previously, lifting the regulatory risk for this class of drugs.”
Shares of the company are now up 83% year-to-date, and up 22% over the past 12 months.
Here’s a chart showing the pop in shares on Friday: